Key result
NLRP3 inhibition with MCC950 reduced inflammatory response, improved cardiac function, and suppressed tumor growth in a mouse model of ICI-induced cardiotoxicity.
Why the study?
ICI therapy causes cardiotoxicity, but traditional immunosuppressive treatments have limited effectiveness and may accelerate tumor growth, creating a need for approaches that mitigate cardiotoxicity while preserving antitumor immunity.
Does NLRP3 inflammasome inhibition with MCC950 reduce cardiotoxicity and preserve antitumor immunity in melanoma-bearing mice treated with immune checkpoint inhibitors?
Does NLRP3 inflammasome inhibition with MCC950 reduce cardiotoxicity and preserve antitumor immunity in melanoma-bearing mice treated with immune checkpoint inhibitors?
NLRP3 inflammasome inhibition represents a promising approach to abrogate ICI-induced cardiotoxicity without compromising antitumor efficacy.
May reduce ICI cardiotoxicity while preserving antitumor immunity; hypothesis-generating and requires prospective validation before clinical adoption.
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many malignant tumors. However, ICI-induced hyper-immune activation causes cardiotoxicity. Traditional treatments such as glucocorticoids and immunosuppressants have limited effectiveness and may even accelerate tumor growth. This study aimed to identify approaches that effectively reduce cardiotoxicity and simultaneously preserve or enhance the antitumor immunity of ICI therapy. METHODS: ICI injection in melanoma-bearing C57BL/6J female mice was used to simulate cardiotoxicity in patients with tumor undergoing immune therapy. MCC950 was used to block nod-like receptor protein 3 (NLRP3) inflammasome activity. Echocardiography, immunofluorescence, flow cytometry, and reverse transcription quantitative polymerase chain reaction were used to assess cardiac function, immune cell populations, and inflammatory factor levels. Bulk and single-cell RNA sequencing was used to detect the changes in cardiac transcriptome and immunological network. RESULTS: NLRP3 inhibition reduced inflammatory response and improved cardiac function. Notably, NLRP3 inhibition also resulted in a pronounced suppression of tumor growth. Single-cell RNA sequencing elucidated that MCC950 treatment reduced the cardiac infiltration of pathogenic macrophages, cytotoxic T cells, activated T cells, and their production of inflammatory cytokines, while enhancing the presence of reparative macrophages and naive T cells. In addition, MCC950 attenuated cardiotoxicity induced by dual programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immunotherapy and promoted tumor regression, and showed efficacy in treating established cardiotoxicity. CONCLUSIONS: Our findings provide a promising clinical approach for preventing and treating cardiotoxicity induced by ICIs, dissociating the antitumor efficacy of ICI-based therapies from their cardiotoxic side effects.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied Immune checkpoint inhibitor-induced cardiotoxicity. MCC950 (NLRP3 inflammasome inhibitor) was evaluated on Cardiac function, immune cell populations, inflammatory factor levels, and tumor growth. NLRP3 inhibition with MCC950 reduced inflammatory response, improved cardiac function, and suppressed tumor growth in a mouse model of ICI-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: